BioLineRx (BLRX) Research & Development (2011 - 2025)
BioLineRx (BLRX) posted quarterly Research & Development of -$2.4 million for Q4 2025, down 30.03% year-over-year from -$3.5 million in Q4 2024, and down 41.07% quarter-over-quarter from -$1.7 million in Q3 2025.
BioLineRx (BLRX) Research & Development (2011 - 2025) Analysis & Trends
BioLineRx's Research & Development history runs 14 years deep, the most recent figure standing at -$2.4 million for Q4 2025.
- In Q4 2025, Research & Development fell 30.03% year-over-year to -$2.4 million; the TTM figure through Dec 2025 stood at -$8.1 million (up 11.54% YoY), while the FY2025 annual figure was -$8.1 million, up 11.54% from the prior year.
- Research & Development for Q4 2025 stood at -$2.4 million, down from -$1.7 million in the prior quarter.
- The five-year high for Research & Development was $5.4 million in Q2 2022, with the low at -$5.1 million in Q4 2021.
- The 5-year median for Research & Development is -$2.6 million (2023), against an average of -$2.3 million.
- The sharpest annual moves came in 2023 and 2024: Research & Development slumped 155.72% in 2023, then surged 39.88% in 2024.
- BioLineRx's Research & Development stood at -$5.1 million in 2021, then surged by 33.09% to -$3.4 million in 2022, then gained by 9.56% to -$3.1 million in 2023, then soared by 39.88% to -$1.9 million in 2024, then slumped by 30.03% to -$2.4 million in 2025.
- Business Quant data shows BLRX's Research & Development at -$2.4 million in Q4 2025, -$1.7 million in Q3 2025, and -$2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | BioLineRx | 7.21 Bn | 7.21 Bn | 154,000.00 | -2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.43 Mn |
| Sep 30, 2025 | -1.72 Mn |
| Jun 30, 2025 | -2.33 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Dec 31, 2024 | -1.87 Mn |
| Sep 30, 2024 | -2.57 Mn |
| Jun 30, 2024 | -2.23 Mn |
| Mar 31, 2024 | -2.49 Mn |
| Dec 31, 2023 | -3.10 Mn |
| Sep 30, 2023 | -2.73 Mn |
| Jun 30, 2023 | -3.01 Mn |
| Mar 31, 2023 | -3.68 Mn |
| Dec 31, 2022 | -3.43 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | 5.40 Mn |
| Mar 31, 2022 | -4.44 Mn |
| Dec 31, 2021 | -5.13 Mn |
| Sep 30, 2021 | -4.92 Mn |
| Jun 30, 2021 | 5.14 Mn |
| Mar 31, 2021 | -4.28 Mn |